Search

Tuberculosis (TB) is a bacterial infection responsible for more than 1.5 million deaths per year. The emergence of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) poses an urgent need for novel antituberculosis drugs. Filamentous temperature-sensitive protein Z (FtsZ) is a bacterial homologue of mammalian tubulin. During bacterial cell division, FtsZ first polymerises into protofilaments in a GTP-dependent manner to form a highly dynamic cytokinetic structure, namely the Z-ring, at a cell midpoint. The Z-ring contracts resulting in septum formation and cell division. Thus, the FtsZ function is essential; indeed, its inhibition leads to the disruption of cell division and eventually bacterial cell death. The development of Mycobacterium tuberculosis FtsZ inhibitors has been hampered by a lack of structural data that could be exploited for structure-based drug design with a strong possibility of identifying false positive inhibitors using traditional drug discovery approaches. Through attempts to advance structural biology and the development of M. tuberculosis FtsZ inhibitors, first, we determined various crystal structures of M. tuberculosis FtsZ in complex with coumarin analogues (well established FtsZ inhibitors), revealing that coumarins exclusively bind to two novel cryptic pockets in nucleotide-free FtsZ, but not to binary FtsZ-GTP or -GDP complexes. Second, NMR-based fragment screening to identify novel FtsZ inhibitors was carried out in collaboration with our partners at Monash University, resulting in 38 fragments hits. These were further validated by biophysical and biochemical assays as well as X-ray crystallography to rank them for further development as lead compounds. Two fragments, A11 and B2, were selected for this development using structure-based drug design. A11 and B2 were successfully crystallised in complexes with FtsZ, in which transient binding pockets in M. tuberculosis FtsZ were further confirmed. Overall, the results of these studies help in our understanding of the mechanism of the cryptic pocket formation of M. tuberculosis FtsZ and also in advancing the development of M. tuberculosis FtsZ inhibitors using structure-based drug design.